New-onset acute psychosis as a manifestation of lupus cerebritis following concomitant COVID-19 infection and vaccination: a rare case report

Fekih‐Romdhane, Feten; Ghrissi, F.; Hallit, Souheil; Cheour, Majda

doi:10.1186/s12888-023-04924-4

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the treatment of GBS, the use of intravenous immunoglobulin (IVIG) can be associated with elevated ANA levels, although in our patients the ANAs were tested prior to the use of IVIG and this may be a coincidental finding [31]. Recently, the induction of ANA, ENA, and autoimmune diseases, such as lupus cerebritis, autoimmune hepatitis, and glomerulonephritis, among others, has been reported after COVID-19 vaccination [32][33][34]. However, according to a study, no ANA induction or increase was observed after administering the second dose of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2, six months after vaccination.…”

Section: Discussionmentioning

confidence: 78%

New Onset Autoimmune Diseases after the Sputnik Vaccine

et al. 2023

View full text Add to dashboard Cite

The vertiginous advance for identifying the genomic sequence of SARS-CoV-2 allowed the development of a vaccine including mRNA-based vaccines, inactivated viruses, protein subunits, and adenoviral vaccines such as Sputnik. This study aims to report on autoimmune disease manifestations that occurred following COVID-19 Sputnik vaccination. Patients and Methods: A retrospective study was conducted on patients with new-onset autoimmune diseases induced by a post-COVID-19 vaccine between March 2021 and December 2022, in two referral hospitals in Mexico City and Argentina. The study evaluated patients who received the Sputnik vaccine and developed recent-onset autoimmune diseases. Results: Twenty-eight patients developed recent-onset autoimmune diseases after Sputnik vaccine. The median age was 56.9 ± 21.7 years, with 14 females and 14 males. The autoimmune diseases observed were neurological in 13 patients (46%), hematological autoimmune manifestations occurred in 12 patients (42%), with thrombotic disease observed in 10 patients (28%), and autoimmune hemolytic anemia in two patients (7.1%). Rheumatological disorders were present in two patients (7.1%), and endocrine disorders in one patient (3.5%). Principio del formulario Conclusion: Although the COVID-19 Sputnik vaccine is generally safe, it can lead to adverse effects. Thrombosis and Guillain-Barre were the most frequent manifestations observed in our group of patients.

show abstract

Section: Discussionmentioning

confidence: 78%

New Onset Autoimmune Diseases after the Sputnik Vaccine

et al. 2023

View full text Add to dashboard Cite

show abstract

Tozinameran

2023

Reactions Weekly

View full text Add to dashboard Cite

New-onset psychosis following COVID-19 vaccination: a systematic review

Lazareva,

Renemane,

Vrublevska

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundThe emergence of a new coronavirus strain caused the COVID-19 pandemic. While vaccines effectively control the infection, it’s important to acknowledge the potential for side effects, including rare cases like psychosis, which may increase with the rising number of vaccinations.ObjectivesOur systematic review aimed to examine cases of new-onset psychosis following COVID-19 vaccination.MethodsWe conducted a systematic review of case reports and case series on new-onset psychosis following COVID-19 vaccination from December 1st, 2019, to November 21st, 2023, using PubMed, MEDLINE, ClinicalKey, and ScienceDirect. Data extraction covered study and participant characteristics, comorbidities, COVID-19 vaccine details, and clinical features. The Joanna Briggs Institute quality assessment tools were employed for included studies, revealing no significant publication bias.ResultsA total of 21 articles described 24 cases of new-onset psychotic symptoms following COVID-19 vaccination. Of these cases, 54.2% were female, with a mean age of 33.71 ± 12.02 years. Psychiatric events were potentially induced by the mRNA BNT162b2 vaccine in 33.3% of cases, and psychotic symptoms appeared in 25% following the viral vector ChAdOx1 nCoV-19 vaccine. The mean onset time was 5.75 ± 8.14 days, mostly reported after the first or second dose. The duration of psychotic symptoms ranged between 1 and 2 months with a mean of 52.48 ± 60.07 days. Blood test abnormalities were noted in 50% of cases, mainly mild to moderate leukocytosis and elevated C-reactive protein. Magnetic resonance imaging results were abnormal in 20.8%, often showing fluid-attenuated inversion recovery hyperintensity in the white matter. Treatment included atypical antipsychotics in 83.3% of cases, typical antipsychotics in 37.5%, benzodiazepines in 50%, 20.8% received steroids, and 25% were prescribed antiepileptic medications. Overall, 50% of patients achieved full recovery.ConclusionStudies on psychiatric side effects post-COVID-19 vaccination are limited, and making conclusions on vaccine advantages or disadvantages is challenging. Vaccination is generally safe, but data suggest a potential link between young age, mRNA, and viral vector vaccines with new-onset psychosis within 7 days post-vaccination. Collecting data on vaccine-related psychiatric effects is crucial for prevention, and an algorithm for monitoring and treating mental health reactions post-vaccination is necessary for comprehensive management.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier CRD42023446270.

show abstract

New-onset acute psychosis as a manifestation of lupus cerebritis following concomitant COVID-19 infection and vaccination: a rare case report

Cited by 3 publications

References 44 publications

New Onset Autoimmune Diseases after the Sputnik Vaccine

New Onset Autoimmune Diseases after the Sputnik Vaccine

Tozinameran

New-onset psychosis following COVID-19 vaccination: a systematic review

Contact Info

Product

Resources

About